ECULIZUMAB (SOLIRIS®) PRESCRIBER ORDER FORM



Fax completed form, insurance information, and clinical documentation to:					t 888-386-08	86 f 586-263-3306
Patient Name:				Date of Birth:		
Address:						
Phone:	F	leight:	□ inches	□ cm	Weight:	□lbs □ kg
	CLINICA	L INFORMATI	ON			
Primary Diagnosis Description:			ICD-	10 Code:		
□ Primary vaccination series completed – date: Meningococcal Vaccination Status: □ MenACWY booster completed – date: □ MenB booster completed – date:						
ECI	JLIZUMAB (S	OLIRIS®) PRE	SCRIPTION			
Eculizumab (Soliris®) refill as directed x 1 year						
Induction Dose: ☐ Infuse 600 mg IV over at least 35 min weekly x 4 weeks. ☐ Infuse 900 mg IV over at least 35 min weekly x 4 weeks. ☐ Other:						
Maintenance Dose: ☐ Infuse 900 mg IV over at least 35 min on Week 5, then every 2 weeks thereafter. ☐ Infuse 1200 mg IV over at least 35 min on Week 5, then every 2 weeks thereafter. ☐ Infuse mg IV over at least 35 min every 2 weeks. ☐ Other:						
Max infusion time not to exceed 2 hours.						
	ANCIL	LARY ORDER	S			
Anaphylaxis Kit If this is a 1st dose, would you like Compassurate Yes No Dosage: • Epinephrine 0.3 mg (> 30 kg), 0 • Diphenhydramine 25mg PO or • Normal saline 500 mL (> 30 kg) PRN headache rated > 5 on pai Medication Orders Acetaminophen 650 mg PO 30 min beforate Diphenhydramine 25 mg PO 30 min beforate Diphenhydramine 25 mg PO 30 min beforate NS 2 to 3 mL pre-/postate Implanted Port: NS 5 to 10 mL pre-/postate NS 5 to 10 mL pre-/postate Dorders No labs ordered at this time. Other: Skilled nurse to initiate IV access for administration of infusion. Refill above ancillary orders as directed	.15 mg (15 to 30 IV/IM. May repea or 250 mL (< 30 In scale. e infusion. Patiente infusio	kg), or 0.01 mg/k t additionally 25t kg) IV at KVO rate it may decline. nt may decline. o 20 mL pre-/post to 5 mL every 24	eg (< 15 kg) SQ mg PO or IV PR e PRN anaphyla e-lab draw. Hepa I hr if accessed	or IM x 1; re N. xis. Patient arin (100 u or weekly t	: < 30 kg, infuse nit/mL) 3 to 5 m to monthly if no	over 2 to 4 hours nL post-use. For ot accessed.
I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment.						
Prescriber Signature: Date:						
Prescriber Name:	Phone:	ΠΟΝ	Fax			
Address:		NPI:				
City, State: Zip:		Office Contact:				

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.